Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,022 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Lundin J, Kimby E, Björkholm M, Broliden PA, Celsing F, Hjalmar V, Möllgård L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A. Lundin J, et al. Among authors: waldmann h. Blood. 2002 Aug 1;100(3):768-73. doi: 10.1182/blood-2002-01-0159. Blood. 2002. PMID: 12130484 Free article. Clinical Trial.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
Hale G, Rebello P, Brettman LR, Fegan C, Kennedy B, Kimby E, Leach M, Lundin J, Mellstedt H, Moreton P, Rawstron AC, Waldmann H, Osterborg A, Hillmen P. Hale G, et al. Among authors: waldmann h. Blood. 2004 Aug 15;104(4):948-55. doi: 10.1182/blood-2004-02-0593. Epub 2004 Apr 15. Blood. 2004. PMID: 15090452 Free article. Clinical Trial.
CAMPATH: from concept to clinic.
Waldmann H, Hale G. Waldmann H, et al. Philos Trans R Soc Lond B Biol Sci. 2005 Sep 29;360(1461):1707-11. doi: 10.1098/rstb.2005.1702. Philos Trans R Soc Lond B Biol Sci. 2005. PMID: 16147535 Free PMC article. Review.
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S. Kottaridis PD, et al. Among authors: waldmann h. Blood. 2000 Oct 1;96(7):2419-25. Blood. 2000. PMID: 11001893 Free article. Clinical Trial.
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.
Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW. Chakrabarti S, et al. Among authors: waldmann h. Blood. 2002 Jun 15;99(12):4357-63. doi: 10.1182/blood.v99.12.4357. Blood. 2002. PMID: 12036862 Free article. Clinical Trial.
1,022 results